Skip to main content

Table 1 Demographic and clinical characteristics at baseline

From: Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

 

US

Spain

Australia

Belgium

Patients, n

532

1,345

784

408

Patients who completed 24 months of treatment (evaluated for clinical measures)

   Patients with 24 months of follow-up, n (%)a

209 (39.3)

843 (62.7)

359 (45.8)

262 (64.2)

   Age in years, mean (SD)

42.4 (12.3)

38.8 (11.2)

39.3 (13.0)

41.3 (13.3)

   Male gender, %

64.1

63.2

68.5

63.7

   Years since diagnosis, mean (SD)

18.1 (11.3)

13.1 (9.8)

12.2 (10.4)

10.6 (10.6)

   CGI-S score, mean (SD)

4.6 (1.3)

4.6 (0.9)

4.5 (1.0)

4.7 (1.0)

   GAF score, mean (SD)

48.3 (14.6)

47.8 (15.6)

42.3 (14.5)

43.3 (12.0)

Patients with ≥1 post-baseline visit (evaluated for psychiatric hospitalization rate)

   Patients with ≥1 post-baseline visit, n (%)a

435 (81.8)

1,339 (99.6)

734 (93.6)

393 (96.3)

   Age in years, mean (SD)

41.9 (12.6)

38.4 (11.2)

37.1 (12.5)

40.3 (13.3)

   Male gender, %

66.7

63.6

69.9

62.8

   Years since diagnosis, mean (SD)

17.6 (12.1)

12.6 (9.5)

10.7 (9.5)

9.5 (10.2)

   Hospitalized in the year before RLAT initiation, %

39.3

35.0

76.8

71.2

   CGI-S score, mean (SD)

3.9 (1.2)

4.6 (0.9)

4.6 (1.0)

4.7 (1.0)

   GAF score, mean (SD)

53.1 (13.7)

46.9 (15.2)

42.7 (14.4)

43.6 (12.5)

  1. aBased on total patient population.
  2. CGI-S = Clinical Global Impressions—Severity; GAF = Global Assessment of Functioning; RLAT = risperidone long-acting therapy.